A Combination of Trimethoprimsulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against Stenotrophomonas maltophilia
- Author:
Nabilah Ismail
;
Siti Asma Hassan
;
Zaidah Abdul
- Publication Type:Journal Article
- Keywords:
combination, trimethoprim-sulfamethoxazole, ceftazidime, Stenotrophomonas maltophilia
- From:Malaysian Journal of Medical Sciences
2017;24(2):21-27
- CountryMalaysia
- Language:English
-
Abstract:
Background: Stenotrophomonas maltophilia has emerged as an important nosocomial
pathogen, capable of causing a wide spectrum of infections. Treatment is difficult because it is
resistant to many antimicrobial agents, thus reducing the treatment options. The aims of this
study were to describe the antimicrobial susceptibility patterns and synergistic effect of selected
antimicrobial combinations against S. maltophilia isolates.
Methods: This was a descriptive cross-sectional study undertaken in the Hospital
Universiti Sains Malaysia from April 2011 to March 2012. S. maltophilia isolated from various
clinical specimens were included in the study. Antimicrobial susceptibility testing was done
using the epsilometer test (E-test) and interpreted according to the guidelines of the Clinical and
Laboratory Standards Institute. In the synergy test, the isolates were tested against six different
antimicrobial combinations.
Results: In total, 84 S. maltophilia isolates were collected and analysed. According
to the E-test, the antimicrobial susceptibility of trimethoprim-sulfamethoxazole (TMP-SMX),
tigecycline, and ciprofloxacin was 100%, 91.1%, and 88.9% respectively. The antimicrobial
combination of TMP-SMX and ceftazidime showed the highest synergistic effect.
Conclusion: TMP-SMX remains the antimicrobial of choice to treat S. maltophilia
infection. TMP-SMX and ceftazidime was the most effective combination in vitro.
- Full text:P020170508358733848289.pdf
